

S1 File. References: Included studies

29. George A, Riddell D, Seal S, Talukdar S, Mahamdallie S, Ruark E, et al. Implementing rapid, robust, costeffective, patient-centred, routine genetic testing in ovarian cancer patients. *Sci. Rep.* 2016; doi: 10.1038/srep29506.
30. Percival N, George A, Gyertson J, Hamill M, Fernandes A, Davies E, et al. The integration of BRCA testing into oncology clinics. *Br J Nurs.* 2016;12:690-694
31. Plaskocinska I, Shipman H, Drummond J, Thompson E, Buchanan V, Newcombe B, et al. New paradigms for BRCA1/BRCA2 testing in women with ovarian cancer: results of the Genetic Testing in Epithelial Ovarian Cancer (GTEOC) study. *J Med Genet.* 2016; doi:10.1136/jmedgenet-2016-10390.
32. Rahman B, Lanceley A, Kristeleit RS, Ledermann JA, McCormack M, et al. Mainstreamed genetic testing for women with ovarian cancer: first-year experience. *J Med Genet.* 2019;56:195–198.
33. Kentwell M, Dow E, Antill Y, Wrede CD, McNally O, Higgs E, et al. Mainstreaming cancer genetics: A model integrating germline BRCA testing into routine ovarian cancer clinics. *Gynecol Oncol.* 2017;145:130-136.
34. Senter L, O'Malley DM, Backes FJ, Copeland LJ, Fowler JM, Salani, R, et al. Genetic consultation embedded in a gynecologic oncology clinic improves compliance with guideline-based care. *Gynecol Oncol.* 2017;147:110–114.
35. Bednar EM, Oakley HD, Sun CC, Burke CC, Munsell MF, Westin SN, et al. A universal genetic testing initiative for patients with high-grade, non-mucinous epithelial ovarian cancer and the implications for cancer treatment. *Gynecol Oncol.* 2017;146 399–404.

36. Uyar D, Neary J, Monroe A, Nugent M, Simpson P, Geurts JL. Implementing a quality improvement project for universal genetic testing in women with ovarian cancer. *Gynecol Oncol*. 2018 doi 10.1016/j.ygyno.2018.03.0590090-8258/
37. Swanson CL, Kumar A, Maharaj JM, Kemppainen JL, Thomas BC, Weinhold MR, et al. Increasing genetic counseling referral rates through bundled interventions after ovarian cancer diagnosis. *Gynecol Oncol*. 2018;149:121–126.
38. Brown J, Athens A, Tait DL, Crane EK, Higgins RVR, Naumann W, et al. A Comprehensive Program Enabling Effective Delivery of Regional Genetic Counseling. *Int J Gynecol Cancer*. 2018;28: 996-1002.
39. Bednar EM, Sun CC, Camacho B, Terrell J, Rieber AG, Ramondetta L, et al. Disseminating universal genetic testing to a diverse, indigent patient population at a county hospital gynecologic oncology clinic. *Gynecol Oncol*. 2019;152: 328–333.
40. Kemp Z, Turnbull A, Yost S, Seal S, Mahamdallie S, Poyastro-Pearson E,et al. Evaluation of Cancer-Based Criteria for Use in Mainstream BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer. *JAMA Network Open*. 2019; doi: 10.1001/jamanetworkopen.2019.4428
41. Miesfeldt S, Feero WG, Lucas FL, Rasmussen K. Association of patient navigation with care coordination in a Lynch syndrome screening program. *Transl Behav Med*. 2018 23;8:450-455.
42. Long JC, Debono D, Williams R, Salisbury E, O'Neill S, Eykman E,et al. Using behaviour change and implementation science to address low referral rates in oncology. *BMC Health Serv Res*. 2018 18:904

43. Cohen PA, Nichols CB, Schofield L, Van Der Werf S, Pachter N. Impact of Clinical Genetics Attendance at a Gynecologic Oncology Tumor Board on Referrals for Genetic Counseling and BRCA Mutation Testing. *Int J of Gynecol Cancer*. 2016;26:892-897.
44. Heald B, Plesec T, Liu X, Pai R, Patil D, Moline J, et al. Implementation of Universal Microsatellite Instability and Immunohistochemistry Screening for Diagnosing Lynch Syndrome in a Large Academic Medical Center. *J Clin Oncol*. 2013;31:1336-1340.
45. Hanley GE, McAlpine JN, Miller D, Huntsman D, Schrader KA, Gilks CB, et al. A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention. *BMC Cancer*. 2018; 18:254.
46. Petzel SV, Vogel RI, McNeil J, Leininger, A, Argenta, PA, Geller MA. Improving Referral for Genetic Risk Assessment in Ovarian Cancer Using an Electronic Medical Record System. *Int J of Gynecol Cancer*. 2014;24:1003-1009.
47. Cohen SA, Laurino M, Bowen DJ, Upton MP, Pritchard C, Grady WM. Initiation of Universal Tumor Screening for Lynch Syndrome in Colorectal Cancer Patients as a Model for the Implementation of Genetic Information Into Clinical Oncology Practice. *Cancer*. 2016; 393-401.
48. Tutty E, Petelin L, McKinley J, Young M, Meiser B, Rasmussen VM, et al. Evaluation of telephone genetic counselling to facilitate germline BRCA1/2 testing in women with high-grade serous ovarian cancer. *Eur J Hum Genet*. 2019; doi.org/10.1038/s41431-019-0390-9
49. Meiser B, Gleeson M, Kasparian N, Barlow-Stewart K, Ryan M, Watts K, et al. There is no decision to make: Experiences and attitudes toward treatment-focused genetic testing among women diagnosed with ovarian cancer. *Gynecol Oncol*. 2012;124:153-157.

50. Shipman H, Flynn S, MacDonald-Smith CF, Brenton J, Crawford R, et al. Universal BRCA1/BRCA2 Testing for Ovarian Cancer Patients is Welcomed, but with Care: How Women and Staff Contextualize Experiences of Expanded Access. *J Genet Counsel.* 2017; 26:1280–1291
51. McLeavy L, Rahman B, Kristeleit R, Ledermann J, Lockley M, McCormack M, et al. Mainstreamed genetic testing in ovarian cancer: patient experience of the testing process. *Int J Gynecol Cancer.* 2020;30:221–226.
52. Rumford M, Lythgoe M, McNeish I, Gabra H, Tookman L, Rahman N, et al. Oncologist-led BRCA ‘mainstreaming’ in the ovarian cancer clinic: A study of 255 patients and its impact on their management. *Sci Rep.* 2020 10:3390
53. Grindeland EM, Jørgensen K, Olsson P, Gravdehaug B, Lurås H, Schlichting E, et al. Mainstreamed genetic testing of breast cancer patients in two hospitals in South Eastern Norway. *Fam Cancer.* 2020;19:133–142.
54. Richardson M, Jung Min H, Hong Q, Compton K, Wing Mung S, Lohn Z, et al. Oncology Clinic-Based Hereditary Cancer Genetic Testing in a Population-Based Health Care System. *Cancers.* 2020;12:338.
55. Lobo M, López-Tarruella S, Luque S, Lizarraga S, Flores-Sánchez C, Bueno O, et al. Evaluation of Breast Cancer Patients with Genetic Risk in a University Hospital: Before and After the Implementation of a Heredofamilial Cancer Unit. *J Genet Couns.* 2018; 27:854–862.

